Alloimmunization following blood transfusion.
Alloimmunization following blood transfusion.
复制标题
输血后的同种免疫。
DOI：
--
复制
发表时间：
1989
影响因子：
4.6
通讯作者：
Hartrick Mb
中科院分区：
文献类型：
--
作者：
R. Walker;Lin Dt;Hartrick Mb
虽然Rh免疫球蛋白（Rhlg）在美国广泛应用已有20年，但抗d抗体仍然是医院患者中常见的同种异体抗体。目前，作为具有临床意义的同种抗体，抗- d的出现频率仅次于抗- k。对住院患者同种抗体频率的估计显示，抗d和抗cd的频率逐渐下降，而抗k、抗e和抗jka的相对频率和绝对频率均呈上升趋势。这一现象可能反映了红细胞使用因子（红细胞输注—自体输注）/入院患者对Rhlg的最佳使用和更积极的输血治疗。这种做法可能是住院病人病情日益严重的结果。由于供体白细胞、血小板和血清蛋白引起的同种异体免疫也经常在输入同种异体血液后发生。这些问题可能会给输血接受者带来额外的风险。
Although it has been 20 years since Rh immunoglobulin (Rhlg) was widely introduced in the United States, anti-D still remains as a frequent alloantibody found in hospital patients. Currently, anti-D is second in frequency only to anti-K as an alloantibody of clinical significance. Estimation of alloantibody frequencies in hospital patients reveals a gradual decline in the frequencies of anti-D and anti-CD, whereas anti-K, anti-E and anti-Jka show increases in relative and absolute frequencies. This phenomenon probably reflects the optimum use of Rhlg and more aggressive transfusion treatment of patients as indicated by the red cell use factor: (Red cell transfusions -- autologous transfusions)/admissions. Such a practice may be the result of the increasing severity of illness observed in patients admitted to hospitals. Alloimmunization due to donor white blood cells, platelets, and serum proteins also frequently follows the transfusion of homologous blood. These problems, which may pose additional risks to the transfusion recipient, are reviewed.